MIFH
HOWL icon

Migdal Insurance & Financial Holdings’s Werewolf Therapeutics HOWL Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-187,500
Closed -$825K – 624
2022
Q1 		$825K Hold
187,500
– – 0.01% 193
2021
Q4 		$2.23M Hold
187,500
– – 0.02% 167
2021
Q3 		$3.22M Hold
187,500
– – 0.03% 149
2021
Q2 		$3.27M Buy
+187,500
New +$2.57M 0.03% 151

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Migdal Insurance & Financial Holdings's HOWL Position: Q2 2022 in Review

Migdal Insurance & Financial Holdings sold out of Werewolf Therapeutics (HOWL) in Q2 2022, closing a stake of 187,500 shares — an estimated $825K sold.

Migdal Insurance & Financial Holdings first reported a position in HOWL in Q2 2021 and held it in 4 quarters. The position peaked at $3.27M in Q2 2021. 46 funds tracked by Wall St. Rank hold HOWL as of Q2 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Werewolf Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 187,500 Werewolf Therapeutics shares in Q2 2022, an estimated $825K.
  • Migdal Insurance & Financial Holdings first reported a position in Werewolf Therapeutics in Q2 2021 and held it in 4 quarters.
  • Migdal Insurance & Financial Holdings's Werewolf Therapeutics position peaked at $3.27M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2022, filed 10 Aug 2022.